search
Back to results

Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan (STEADFAST)

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Vildagliptin
Gliclazide
Metformin
Placebo to Gliclazide
Placebo to Vildagliptin
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Type 2 Diabetes Mellitus, Ramadan, Vildagliptin, Hypoglycemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Confirmed Type 2 Diabetes diagnosis
  • Plan to fast during Ramadan
  • Treated with a combination of metformin and an Sulfonylurea (SU) for at least 12 weeks and HbA1c ≤8.5% at Visit 1
  • Taking a sulfonylurea treatment for less than 3 years prior to Visit 1
  • Body mass index (BMI) ≥22 and ≤45 kg/m2 at Visit 1

Exclusion Criteria:

  • Pregnant or nursing (lactating) women
  • History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.
  • Patients who are taking any other anti-diabetes drug (oral or injection) other than metformin and an SU component.
  • Inability to comply with the study procedures or medications.

"Other protocol-defined inclusion/exclusion criteria may apply"

Sites / Locations

  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Vildagliptin + placebo to Gliclazide

Gliclazide + placebo to Vildagliptin

Arm Description

Vildagliptin tablets will be given at 50mg twice daily (bid). Placebo to Gliclazide capsules will be given at an equivalent dose to previous sulfonylurea in multiples of 80mg only (80-320 mg/day). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.

Gliclazide capsules will be given in multiples of 80 mg (80-320 mg/day) at a dose equivalent to previous sulfonylurea dose, unless at the investigator's discretion it could be up-titrated to the next available dose (if HbA1c is higher than 7.5%). Placebo to Vildagliptin tablets will be given at 50mg twice daily (bid). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.

Outcomes

Primary Outcome Measures

Percentage of patients experiencing at least one Hypoglycaemic Event (HE) during the Ramadan fasting period to test superiority

Secondary Outcome Measures

Percentage of patients without an increase in HbA1c (≤ 0.3%) and with no Hypoglycaemic Events (HEs)
Change from baseline to endpoint in glycosylated hemoglobin (HbA1c)
Endpoint is defined as the visit 4 (post-Ramadan) measurement or the last observation obtained during or after Ramadan, prior to or at initiation of rescue medication
Change from visit 3 (pre-Ramadan visit) to endpoint in glycosylated hemoglobin (HbA1c)
Endpoint is defined as the visit 4 (post-Ramadan) measurement or the last observation obtained during or after Ramadan, prior to or at initiation of rescue medication
Proportion of patients experiencing severe hypoglycemic events during the Ramadan fasting period
mean amplitude of glycemic excursions (MAGE) to measure glucose fluctuations during the day
assessed in a selected subgroup of patients
Treatment adherence during the Ramadan fasting period
Change from visit 3 (pre-Ramadan visit) to endpoint in body weight
Endpoint is defined as the visit 4 (post-Ramadan) measurement or the last observation obtained during or after Ramadan, prior to or at initiation of rescue medication
Number of unscheduled visit to health care professional
Number of days fasted during the Ramadan fasting period
Number of patients with treatment emergent adverse events (AEs), serious AEs, discontinuation due to AEs, deaths or laboratory abnormalities as assessment of safety and tolerability

Full Information

First Posted
December 24, 2012
Last Updated
October 16, 2013
Sponsor
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01758380
Brief Title
Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan
Acronym
STEADFAST
Official Title
A Double Blind, Double Dummy, Randomised, Multi-centre Study to Assess the Tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan
Study Type
Interventional

2. Study Status

Record Verification Date
October 2013
Overall Recruitment Status
Completed
Study Start Date
January 2013 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
September 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To evaluate vildagliptin as compared to gliclazide, given in combination with metformin in Muslim patients with type 2 diabetes fasting during Ramadan.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Type 2 Diabetes Mellitus, Ramadan, Vildagliptin, Hypoglycemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
557 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Vildagliptin + placebo to Gliclazide
Arm Type
Experimental
Arm Description
Vildagliptin tablets will be given at 50mg twice daily (bid). Placebo to Gliclazide capsules will be given at an equivalent dose to previous sulfonylurea in multiples of 80mg only (80-320 mg/day). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
Arm Title
Gliclazide + placebo to Vildagliptin
Arm Type
Active Comparator
Arm Description
Gliclazide capsules will be given in multiples of 80 mg (80-320 mg/day) at a dose equivalent to previous sulfonylurea dose, unless at the investigator's discretion it could be up-titrated to the next available dose (if HbA1c is higher than 7.5%). Placebo to Vildagliptin tablets will be given at 50mg twice daily (bid). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
Intervention Type
Drug
Intervention Name(s)
Vildagliptin
Other Intervention Name(s)
Galvus
Intervention Description
Patients will be instructed to take Vildagliptin tablets at a fixed dose of 50 mg twice daily (double blind therapy)
Intervention Type
Drug
Intervention Name(s)
Gliclazide
Intervention Description
Patients will be instructed to take Gliclazide capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
Intervention Type
Drug
Intervention Name(s)
Metformin
Intervention Description
Patients in both arms will take Metformin at a dose between 1500mg-2500mg per day, in an open label fashion
Intervention Type
Drug
Intervention Name(s)
Placebo to Gliclazide
Intervention Description
Patients will be instructed to take the Gliclazide matching placebo capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
Intervention Type
Drug
Intervention Name(s)
Placebo to Vildagliptin
Intervention Description
Patients will be instructed to take Vildagliptin matching placebo tablets at a fixed dose of 50 mg twice daily (double blind therapy).
Primary Outcome Measure Information:
Title
Percentage of patients experiencing at least one Hypoglycaemic Event (HE) during the Ramadan fasting period to test superiority
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Percentage of patients without an increase in HbA1c (≤ 0.3%) and with no Hypoglycaemic Events (HEs)
Time Frame
visit 3 (anytime from week -4 to day -1 before start of Ramadan) to visit 4 (within 4 weeks post-Ramadan fasting period) (minimum 4.5 weeks to maximum 12 weeks) for HbA1c; and during 1 month (Ramadan) for HEs
Title
Change from baseline to endpoint in glycosylated hemoglobin (HbA1c)
Description
Endpoint is defined as the visit 4 (post-Ramadan) measurement or the last observation obtained during or after Ramadan, prior to or at initiation of rescue medication
Time Frame
baseline to visit 4 (within 4 weeks post-Ramadan fasting period) (minimum 12.5 weeks to maximum 30 weeks)
Title
Change from visit 3 (pre-Ramadan visit) to endpoint in glycosylated hemoglobin (HbA1c)
Description
Endpoint is defined as the visit 4 (post-Ramadan) measurement or the last observation obtained during or after Ramadan, prior to or at initiation of rescue medication
Time Frame
visit 3 (anytime from week-4 to day-1 before start of Ramadan) to visit 4 (within 4 weeks post-Ramadan fasting period) (minimum 4.5 weeks to maximum 12 weeks)
Title
Proportion of patients experiencing severe hypoglycemic events during the Ramadan fasting period
Time Frame
1 month
Title
mean amplitude of glycemic excursions (MAGE) to measure glucose fluctuations during the day
Description
assessed in a selected subgroup of patients
Time Frame
72 hours
Title
Treatment adherence during the Ramadan fasting period
Time Frame
1 month
Title
Change from visit 3 (pre-Ramadan visit) to endpoint in body weight
Description
Endpoint is defined as the visit 4 (post-Ramadan) measurement or the last observation obtained during or after Ramadan, prior to or at initiation of rescue medication
Time Frame
From visit 3 (anytime from week-4 to day-1 before start of Ramadan) to visit 4 (within 4 weeks post-Ramadan fasting period) (minimum 4.5 weeks to maximum 12 weeks)
Title
Number of unscheduled visit to health care professional
Time Frame
From visit 3 (anytime from week-4 to day-1 before start of Ramadan) to visit 4 (within 4 weeks post-Ramadan fasting period) (minimum 4.5 weeks to maximum 12 weeks)
Title
Number of days fasted during the Ramadan fasting period
Time Frame
1 month
Title
Number of patients with treatment emergent adverse events (AEs), serious AEs, discontinuation due to AEs, deaths or laboratory abnormalities as assessment of safety and tolerability
Time Frame
Baseline to visit 4 (within 4 weeks post-Ramadan fasting period) (minimum 12.5 weeks to maximum 30 weeks)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Confirmed Type 2 Diabetes diagnosis Plan to fast during Ramadan Treated with a combination of metformin and an Sulfonylurea (SU) for at least 12 weeks and HbA1c ≤8.5% at Visit 1 Taking a sulfonylurea treatment for less than 3 years prior to Visit 1 Body mass index (BMI) ≥22 and ≤45 kg/m2 at Visit 1 Exclusion Criteria: Pregnant or nursing (lactating) women History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes. Patients who are taking any other anti-diabetes drug (oral or injection) other than metformin and an SU component. Inability to comply with the study procedures or medications. "Other protocol-defined inclusion/exclusion criteria may apply"
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharma AG
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Investigative Site
City
Frederiksberg
ZIP/Postal Code
1819
Country
Denmark
Facility Name
Novartis Investigative Site
City
Alexandria
ZIP/Postal Code
21131
Country
Egypt
Facility Name
Novartis Investigative Site
City
Cairo
ZIP/Postal Code
11566
Country
Egypt
Facility Name
Novartis Investigative Site
City
Augsburg
ZIP/Postal Code
86150
Country
Germany
Facility Name
Novartis Investigative Site
City
Augsburg
ZIP/Postal Code
86159
Country
Germany
Facility Name
Novartis Investigative Site
City
Bad Oeynhausen
ZIP/Postal Code
32549
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
10997
Country
Germany
Facility Name
Novartis Investigative Site
City
Dortmund
ZIP/Postal Code
44137
Country
Germany
Facility Name
Novartis Investigative Site
City
Einbeck
ZIP/Postal Code
37574
Country
Germany
Facility Name
Novartis Investigative Site
City
Loehne
ZIP/Postal Code
32584
Country
Germany
Facility Name
Novartis Investigative Site
City
Meine
ZIP/Postal Code
38527
Country
Germany
Facility Name
Novartis Investigative Site
City
München
ZIP/Postal Code
80339
Country
Germany
Facility Name
Novartis Investigative Site
City
Saarlouis
ZIP/Postal Code
66740
Country
Germany
Facility Name
Novartis Investigative Site
City
Malang
State/Province
East Java
ZIP/Postal Code
65111
Country
Indonesia
Facility Name
Novartis Investigative Site
City
Surabaya
State/Province
East Java
ZIP/Postal Code
60286
Country
Indonesia
Facility Name
Novartis Investigative Site
City
Padang
State/Province
Sumatera Barat
ZIP/Postal Code
25127
Country
Indonesia
Facility Name
Novartis Investigative Site
City
Jakarta
ZIP/Postal Code
10220
Country
Indonesia
Facility Name
Novartis Investigative Site
City
Jakarta
ZIP/Postal Code
10430
Country
Indonesia
Facility Name
Novartis Investigative Site
City
Amman
ZIP/Postal Code
11196
Country
Jordan
Facility Name
Novartis Investigative Site
City
Kuwait
ZIP/Postal Code
1180
Country
Kuwait
Facility Name
Novartis Investigative Site
City
Beirut
ZIP/Postal Code
1107 2020
Country
Lebanon
Facility Name
Novartis Investigative Site
City
Beirut
Country
Lebanon
Facility Name
Novartis Investigative Site
City
Hazmieh
ZIP/Postal Code
470
Country
Lebanon
Facility Name
Novartis Investigative Site
City
Saida
Country
Lebanon
Facility Name
Novartis Investigative Site
City
Kota Bahru
State/Province
Kelantan
ZIP/Postal Code
16150
Country
Malaysia
Facility Name
Novartis Investigative Site
City
Kuala Lumpur
ZIP/Postal Code
59100
Country
Malaysia
Facility Name
Novartis Investigative Site
City
Krasnodar
ZIP/Postal Code
350063
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Penza
ZIP/Postal Code
440026
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Rostov on Don
ZIP/Postal Code
344000
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Rostov-on-Don
ZIP/Postal Code
344718
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Saratov
ZIP/Postal Code
410012
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
St. Petersburg
ZIP/Postal Code
191015
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
St.- Petersburg
ZIP/Postal Code
199034
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Ufa
ZIP/Postal Code
450000
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Dammam
ZIP/Postal Code
40145
Country
Saudi Arabia
Facility Name
Novartis Investigative Site
City
Riyadh
ZIP/Postal Code
11426
Country
Saudi Arabia
Facility Name
Novartis Investigative Site
City
Singapore
ZIP/Postal Code
440080
Country
Singapore
Facility Name
Novartis Investigative Site
City
Singapore
ZIP/Postal Code
545025
Country
Singapore
Facility Name
Novartis Investigative Site
City
Singapore
ZIP/Postal Code
659164
Country
Singapore
Facility Name
Novartis Investigative Site
City
Málaga
State/Province
Andalucia
ZIP/Postal Code
29010
Country
Spain
Facility Name
Novartis Investigative Site
City
Barcelona
State/Province
Cataluña
ZIP/Postal Code
08001
Country
Spain
Facility Name
Novartis Investigative Site
City
Girona
State/Province
Cataluña
ZIP/Postal Code
17007
Country
Spain
Facility Name
Novartis Investigative Site
City
Salt
State/Province
Cataluña
ZIP/Postal Code
17190
Country
Spain
Facility Name
Novartis Investigative Site
City
Santa Coloma de Gramanet
State/Province
Cataluña
ZIP/Postal Code
08923
Country
Spain
Facility Name
Novartis Investigative Site
City
Vic
State/Province
Cataluña
ZIP/Postal Code
08500
Country
Spain
Facility Name
Novartis Investigative Site
City
Ceuta
ZIP/Postal Code
51002
Country
Spain
Facility Name
Novartis Investigative Site
City
Melilla
ZIP/Postal Code
52005
Country
Spain
Facility Name
Novartis Investigative Site
City
Le Belvedere - Tunis
State/Province
Tunisie
ZIP/Postal Code
1002
Country
Tunisia
Facility Name
Novartis Investigative Site
City
Sfax
State/Province
Tunisie
ZIP/Postal Code
3029
Country
Tunisia
Facility Name
Novartis Investigative Site
City
Tunis
State/Province
Tunisie
ZIP/Postal Code
1007
Country
Tunisia
Facility Name
Novartis Investigative Site
City
Monastir
ZIP/Postal Code
5000
Country
Tunisia
Facility Name
Novartis Investigative Site
City
Sousse
ZIP/Postal Code
4000
Country
Tunisia
Facility Name
Novartis Investigative Site
City
Tunis
ZIP/Postal Code
1007
Country
Tunisia
Facility Name
Novartis Investigative Site
City
Tunis
Country
Tunisia
Facility Name
Novartis Investigative Site
City
Diskapi / Ankara
ZIP/Postal Code
06770
Country
Turkey
Facility Name
Novartis Investigative Site
City
Istanbul
ZIP/Postal Code
34093
Country
Turkey
Facility Name
Novartis Investigative Site
City
Istanbul
ZIP/Postal Code
34304
Country
Turkey
Facility Name
Novartis Investigative Site
City
Izmir
ZIP/Postal Code
35380
Country
Turkey
Facility Name
Novartis Investigative Site
City
Kahramanmaras
ZIP/Postal Code
46050
Country
Turkey
Facility Name
Novartis Investigative Site
City
Dubai
Country
United Arab Emirates
Facility Name
Novartis Investigative Site
City
Leicester
State/Province
Leicestershire
ZIP/Postal Code
LE5 4PW
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Birmingham
ZIP/Postal Code
B15 2TT
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Birmingham
ZIP/Postal Code
B8 3Sw
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Birmingham
ZIP/Postal Code
B9 5SS
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Bolton
ZIP/Postal Code
BL4 0JR
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Derby
ZIP/Postal Code
DE22 3NE
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
London
ZIP/Postal Code
W6 7HY
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Manchester
ZIP/Postal Code
M13 9WL
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
24920915
Citation
Hassanein M, Abdallah K, Schweizer A. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc Health Risk Manag. 2014 May 28;10:319-26. doi: 10.2147/VHRM.S64038. eCollection 2014.
Results Reference
derived

Learn more about this trial

Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan

We'll reach out to this number within 24 hrs